Cancer Biomarkers Market

Cancer Biomarkers Market (2nd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK, Novel Biomarkers and Other Biomarkers), Type of Cancer (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia) and Key Geographical Regions (North America, Europe and Asia-Pacific)

  • Lowest Price Guaranteed From USD 4,499

  • Companies Covered
    128

  • Pages
    309

  • View Count
    29671

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Research Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates

3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. An Overview of Cancer Biomarkers
5.2.1. Need for Cancer Biomarkers
5.2.2. Identification of a Candidate Biomarker

5.3. Type of Cancer Biomarkers

5.4. Novel Cancer Biomarkers
5.4.1. Tumor Mutation Burden (TMB)
5.4.1.1. Variation of TMB across Multiple Indications
5.4.1.2. Methods for Measurement of TMB
5.4.1.3. Factors Affecting Measurement of TMB
5.4.1.4. Initiatives for Assessment of TMB as a Potential Biomarker

5.4.2. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
5.4.2.1. Variation of MSI across Multiple Indications
5.4.2.2. Methods for Measurement of MSI

5.4.3. Single Nucleotide Variants
5.4.3.1. Variation of SNV across Multiple Indications
5.4.3.2. Methods for Measurement of SNV

5.4.4. Copy Number Variants
5.4.4.1. Variation of CNV across Multiple Indications
5.4.4.2. Methods for Measurement of CNV

5.4.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers

5.5. Future Perspective

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Cancer Biomarker Testing Solutions: Overall Market Landscape
6.2.1. Analysis by Type of Biomarker
6.2.2. Analysis by Profiling Technology Used
6.2.3. Analysis by Analytical Technique Used
6.2.4. Analysis by Turnaround Time
6.2.5. Analysis by Sample Input
6.2.6. Analysis by Type of Nucleic Acid Tested
6.2.7. Analysis by Type of Cancer
6.2.8. Analysis by Application Area

6.3. Cancer Biomarkers Testing Solutions: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Cancer Biomarkers Testing Solutions: Product Competitiveness Analysis
7.4.1. Products Offered by Players Based in North America
7.4.2. Products Offered by Players Based in Europe
7.4.3. Products Offered by Players Based in Asia-Pacific

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Profiles of Leading Cancer Biomarker Testing Solutions Providers
8.2.1. Agilent
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Cancer Biomarker Testing Solutions Portfolio
8.2.1.4. Recent Developments and Future Outlook

8.2.2. ARUP Laboratories
8.2.2.1. Company Overview
8.2.2.2. Cancer Biomarker Testing Solutions Portfolio
8.2.2.3. Recent Developments and Future Outlook

8.2.3. BioReference
8.2.3.1. Company Overview
8.2.3.2. Cancer Biomarker Testing Solutions Portfolio
8.2.3.3. Recent Developments and Future Outlook

8.2.4. Foundation Medicine
8.2.4.1. Company Overview
8.2.4.2. Cancer Biomarker Testing Solutions Portfolio
8.2.4.3. Recent Developments and Future Outlook

8.2.5. OncoDNA
8.2.5.1. Company Overview
8.2.5.2. Cancer Biomarker Testing Solutions Portfolio
8.2.5.3. Recent Developments and Future Outlook

8.2.6. Q² Solutions
8.2.6.1. Company Overview
8.2.6.2. Cancer Biomarker Testing Solutions Portfolio
8.2.6.3. Recent Developments and Future Outlook

8.2.7. Thermo Fisher Scientific
8.2.7.1. Company Overview
8.2.7.2. Financial Information
8.2.7.3. Cancer Biomarker Testing Solutions Portfolio
8.2.7.4. Recent Developments and Future Outlook

8.2.8. YuceBio
8.2.8.1. Company Overview
8.2.8.2. Cancer Biomarker Testing Solutions Portfolio
8.2.8.3. Recent Developments and Future Outlook

8.3. Short Profiles of Other Leading Cancer Biomarkers Testing Solutions Providers
8.3.1. Asper Biogene
8.3.1.1. Company Overview
8.3.1.2. Cancer Biomarker Testing Solutions Portfolio

8.3.2. Caris Life Sciences
8.3.2.1. Company Overview
8.3.2.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.3. CeGaT
8.3.3.1. Company Overview
8.3.3.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.4. Genekor Medical
8.3.4.1. Company Overview
8.3.4.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.5. Guardant Health
8.3.5.1. Company Overview
8.3.5.2. Cancer Biomarker Testing Solutions Portfolio

8.3.6. Labcorp
8.3.6.1. Company Overview
8.3.6.2. Cancer Biomarker Testing Solutions Portfolio

8.3.7. MedGenome
8.3.7.1. Company Overview
8.3.7.2. Cancer Biomarker Testing Solutions Portfolio

8.3.8. NeoGenomics Laboratories
8.3.8.1. Company Overview
8.3.8.2. Cancer Biomarker Testing Solutions Portfolio

8.3.9. Nonacus
8.3.9.1. Company Overview
8.3.9.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.10. Oxford Gene Technology
8.3.10.1. Company Overview
8.3.10.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.11. Personal Genome Diagnostics
8.3.11.1. Company Overview
8.3.18.3. Cancer Biomarkers Testing Solutions Portfolio

8.3.12. PhenoPath
8.3.12.1. Company Overview
8.3.12.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.13. Positive Biosciences
8.3.13.1. Company Overview
8.3.13.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.14. Quest Diagnostics
8.3.14.1. Company Overview
8.3.14.2. Cancer Biomarkers Testing Solutions Portfolio

8.3.15. Tempus
8.3.15.1. Company Overview
8.3.15.2. Cancer Biomarkers Testing Solutions Portfolio

9. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS
9.1. Chapter Overview
9.2. Study Designs for Biomarker-based Clinical Trials
9.2.1. Enrichment Design
9.2.2. All-comers Design
9.2.3. Mixture / Hybrid Design
9.2.4. Adaptive Design

9.3. Regulatory Guidelines for Biomarker-based Clinical Trial Designs

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Cancer Biomarkers: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Registration Year and Trial Status
10.3.4. Analysis by Trial Phase
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.7. Analysis of Enrolled Patient Population by Trial Phase
10.3.8. Analysis by Type of Sponsor / Collaborator
10.3.9. Most Active Players: Distribution by Number of Registered Trials
10.3.10. Analysis by Study Design
10.3.11. Analysis by Type of Cancer
10.3.12. Analysis of Clinical Trials by Geography
10.3.13. Analysis of Clinical Trials by Trial Status and Geography
10.3.14. Analysis of Enrolled Patient Population by Geography
10.3.15. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cancer Biomarkers: Publication Analysis
11.3.1. Analysis by Year of Publication
11.3.2. Analysis by Type of Publication
11.3.3. Analysis by Type of Cancer
11.3.4. Analysis by Copyright Holders
11.3.5. Word Cloud: Emerging Focus Areas
11.3.6. Most Active Publishers: Analysis by Number of Publications
11.3.7. Key Journals: Analysis by Number of Publications
11.3.8. Key Journals: Analysis by Impact Factor

12. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Big Pharma Players: Benchmarking Analysis
12.3.1. Spider Web Analysis: Abbott
12.3.2. Spider Web Analysis: AbbVie
12.3.3. Spider Web Analysis: Amgen
12.3.4. Spider Web Analysis: AstraZeneca
12.3.5. Spider Web Analysis: Bayer
12.3.6. Spider Web Analysis: Boehringer Ingelheim
12.3.7. Spider Web Analysis: Bristol-Myers Squib
12.3.8. Spider Web Analysis: Eli Lilly
12.3.9. Spider Web Analysis: Gilead
12.3.10. Spider Web Analysis: GlaxoSmithKline
12.3.11. Spider Web Analysis: Merck
12.3.12. Spider Web Analysis: Novartis
12.3.13. Spider Web Analysis: Pfizer
12.3.14. Spider Web Analysis: Roche
12.3.15. Spider Web Analysis: Sanofi

12.4. Concluding Remarks

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY
13.1. Chapter Overview
13.2. Companion Diagnostics: Value Chain
13.3. Cost Distribution Across the Value Chain
13.3.1. Costs Associated with Research and Product Development
13.3.2. Costs Associated with Manufacturing and Assembly
13.3.3. Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
13.3.4. Costs Associated with Payer Negotiation and KOL Engagement
13.3.5. Costs Associated with Marketing and Sales

14. FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Growing Focus on Personalized Medicines
14.3. Extent of Biomarker Testing for Various Oncological Disorders
14.4. Increase in Number of Biomarker-based Clinical Trials
14.5. Increased Adoption of Emerging Analytical Techniques for Biomarker Assessment
14.6. Development of Companion Diagnostic Products

15. GLOBAL CANCER BIOMARKERS MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1. Scenario Analysis
15.3.1.1. Conservative Scenario
15.3.1.2. Optimistic Scenario

15.4. Key Market Segmentations

16. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
16.3.1. Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2. Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.3. Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.4. Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.5. Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.6. Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

16.3.7. Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1. Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
16.3.7.1.1. Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.2. Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.3. Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.4. Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.5. Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

16.4. Data Triangulation and Validation

17. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
17.3.1. Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.2. Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.3. Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.4. Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.5. Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.6. Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.7. Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.8. Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.9. Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.10. Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.11. Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

17.4. Data Triangulation and Validation

18. CANCER BIOMARKERS MARKET, BY KEY GEOGRAPHICAL REGIONS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
18.3.1. Cancer Biomarkers Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.1.1. Cancer Biomarkers Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.1.2. Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.3.2. Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.1. Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.2. Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.3. Cancer Biomarkers Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.4. Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.5. Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.3.3. Cancer Biomarkers Market in Aisa-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.1. Cancer Biomarkers Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.2. Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.3. Cancer Biomarkers Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.4. Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.2. Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.2. Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.3.4. Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.1. Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.2. Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.3. Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.4. Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18.4. Data Triangulation and Validation

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Cell IDc
20.2.1. Company Snapshot
20.2.2. Interview Transcript: David Schwartz, Chief Technical Officer and Helen Synder, Former Director of Preclinical Development & Strategic Partnerships

20.3. CeGat
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Kirill Shur, Business Manager

20.4. NeoGenomics Laboratories
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Lawrence Weiss, Former Chief Scientific Officer

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Current Market Landscape (I/II)
Figure 4.2 Executive Summary: Current Market Landscape (II/II)
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Publication Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
Figure 6.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
Figure 6.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Figure 6.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Figure 6.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
Figure 6.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Figure 6.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Figure 6.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
Figure 6.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Figure 6.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Figure 6.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Figure 7.1 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in North America
Figure 7.2 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Europe
Figure 7.3 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Asia-Pacific
Figure 8.1 Agilent: Annual Revenues, FY 2019–FY 2023 (USD Million)
Figure 8.2 Thermo Fisher Scientific: Annual Revenues, FY 2019–FY 2023 (USD Million)
Figure 9.1 Enrichment Clinical Trial Design: Steps Involved
Figure 9.2 All-Comers Clinical Trial Design: Steps Involved
Figure 9.3 Hybrid Clinical Trial Design: Steps Involved
Figure 9.4 Adaptive Clinical Trial Design: Steps Involved
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Clinical Trial Analysis: Distribution by Study Design
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer
Figure 10.11 Most Active Players: Distribution by Number of Registered Trials
Figure 10.12 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.13 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 10.15 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 11.1 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Figure 11.2 Publication Analysis: Distribution by Type of Publication
Figure 11.3 Publication Analysis: Distribution by Type of Cancer
Figure 11.4 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 11.5 Word Cloud Analysis: Emerging Focus Areas
Figure 11.6 Most Active Publishers: Distribution by Number of Publications
Figure 11.7 Key Journals: Distribution by Number of Publications
Figure 11.8 Key Journals: Distribution by Impact Factor
Figure 12.1 Spider Web Analysis: Abbott
Figure 12.2 Spider Web Analysis: AbbVie
Figure 12.3 Spider Web Analysis: Amgen
Figure 12.4 Spider Web Analysis: AstraZeneca
Figure 12.5 Spider Web Analysis: Bayer
Figure 12.6 Spider Web Analysis: Boehringer Ingelheim
Figure 12.7 Spider Web Analysis: Bristol-Myers Squib
Figure 12.8 Spider Web Analysis: Eli Lilly
Figure 12.9 Spider Web Analysis: Gilead
Figure 12.10 Spider Web Analysis: GlaxoSmithKline
Figure 12.11 Spider Web Analysis: Merck
Figure 12.12 Spider Web Analysis: Novartis
Figure 12.13 Spider Web Analysis: Pfizer
Figure 12.14 Spider Web Analysis: Roche
Figure 12.15 Spider Web Analysis: Sanofi
Figure 12.16 Benchmarking Analysis: Big Pharma players
Figure 13.1 Companion Diagnostics: Value Chain
Figure 13.2 Cost Distribution Across Value Chain
Figure 13.3 Costs Associated with Research and Product Development
Figure 13.4 Costs Associated with Manufacturing and Assembly
Figure 13.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 13.6 Costs Associated with Payer Negotiation and KOL Engagement
Figure 13.7 Costs Associated with Marketing and Sales
Figure 14.1 Cancer Biomarkers Market: Future Growth Opportunities
Figure 15.1 Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 15.2 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 15.3 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 16.1 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
Figure 16.2 Cancer Biomarkers Market for HER2 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.3 Cancer Biomarkers Market for MET Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.4 Cancer Biomarkers Market for EGFR Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.5 Cancer Biomarkers Market for PD-L1 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.6 Cancer Biomarkers Market for NTRK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.7 Cancer Biomarkers Market for ALK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.8 Cancer Biomarkers Market for Other Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.9 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
Figure 16.10 Cancer Biomarkers Market for SNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.12 Cancer Biomarkers Market for MSI Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.13 Cancer Biomarkers Market for CNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.14 Cancer Biomarkers Market for TMB Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.15 Cancer Biomarkers Market for TIL Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.1 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
Figure 17.2 Cancer Biomarkers Market for Breast Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.3 Cancer Biomarkers Market for Prostate Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.4 Cancer Biomarkers Market for Colorectum Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.5 Cancer Biomarkers Market for Lung Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.6 Cancer Biomarkers Market for Thyroid Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.7 Cancer Biomarkers Market for Bladder Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.8 Cancer Biomarkers Market for Melanoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.9 Cancer Biomarkers Market for Non-Hodgkin Lymphoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.10 Cancer Biomarkers Market for Endometrial Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.11 Cancer Biomarkers Market for Kidney Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.12 Cancer Biomarkers Market for Leukemia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.1 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 18.2 Cancer Biomarkers Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3 Cancer Biomarkers Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4 Cancer Biomarkers Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.5 Cancer Biomarkers Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.6 Cancer Biomarkers Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.7 Cancer Biomarkers Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.8 Cancer Biomarkers Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.9 Cancer Biomarkers Market in Spain, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.10 Cancer Biomarkers Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.11 Cancer Biomarkers Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.12 Cancer Biomarkers Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.13 Cancer Biomarkers Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.14 Cancer Biomarkers Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.15 Cancer Biomarkers Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.16 Cancer Biomarkers Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.17 Cancer Biomarkers Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.18 Cancer Biomarkers Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.19 Cancer Biomarkers Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.20 Cancer Biomarkers Market in Argentina, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.21 Cancer Biomarkers Market in Chile, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.22 Cancer Biomarkers Market in Egypt, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.1 Concluding Remarks: Market Landscape
Figure 19.2 Concluding Remarks: Clinical Trial Analysis
Figure 19.3 Concluding Remarks: Publication Analysis
Figure 19.4 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 6.1 Cancer Biomarkers Testing Solutions: Information on Type of Biomarkers
Table 6.2 Cancer Biomarkers Testing Solutions: Information on Profiling Technologies and Analytical Technique
Table 6.3 Cancer Biomarkers Testing Solutions: Information on Turnaround Time, Sample Input and Type of Nucleic Acid Tested
Table 6.4 Cancer Biomarkers Testing Solutions: Information on Type of Cancer
Table 6.5 Cancer Biomarkers Testing Solutions: Information on Application Area and End Users
Table 6.6 List of Cancer Biomarker Testing Solution Providers
Table 8.1 Cancer Biomarkers Testing Solution Providers: List of Companies Profiled
Table 8.2 Agilent: Company Overview
Table 8.3 Agilent: Cancer Biomarkers Testing Solutions Portfolio
Table 8.4 Agilent: Recent Developments and Future Outlook
Table 8.5 ARUP Laboratories: Company Overview
Table 8.6 ARUP Laboratories: Cancer Biomarker Testing Solutions Portfolio
Table 8.7 ARUP Laboratories: Recent Developments and Future Outlook
Table 8.8 BioReference: Company Overview
Table 8.9 BioReference: Cancer Biomarker Testing Solutions Portfolio
Table 8.10 BioReference: Recent Developments and Future Outlook
Table 8.11 Foundation Medicine: Company Overview
Table 8.12 Foundation Medicine: Cancer Biomarker Testing Solutions Portfolio
Table 8.13 Foundation Medicine: Recent Developments and Future Outlook
Table 8.14 OncoDNA: Company Overview
Table 8.15 OncoDNA: Cancer Biomarker Testing Solutions Portfolio
Table 8.16 OncoDNA: Recent Developments and Future Outlook
Table 8.17 Q² Solutions: Company Overview
Table 8.18 Q² Solutions: Cancer Biomarker Testing Solutions Portfolio
Table 8.19 Q² Solutions: Recent Developments and Future Outlook
Table 8.20 Thermo Fisher Scientific: Company Overview
Table 8.21 Thermo Fisher Scientific: Cancer Biomarker Testing Solutions Portfolio
Table 8.22 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.23 YuceBio: Company Overview
Table 8.24 YuceBio: Cancer Biomarker Testing Solutions Portfolio
Table 8.25 Asper Biogene: Company Overview
Table 8.26 Asper Biogene: Cancer Biomarkers Testing Solutions Portfolio
Table 8.27 Caris Life Sciences: Company Overview
Table 8.28 Caris Life Sciences: Cancer Biomarkers Testing Solutions Portfolio
Table 8.29 CeGaT: Company Overview
Table 8.30 CeGaT: Cancer Biomarkers Testing Solutions Portfolio
Table 8.31 Genekor Medical: Company Overview
Table 8.32 Genekor Medical: Cancer Biomarkers Testing Solutions Portfolio
Table 8.33 Guardant Health: Company Overview
Table 8.34 Guardant Health: Cancer Biomarkers Testing Solutions Portfolio
Table 8.35 Labcorp: Company Overview
Table 8.36 Labcorp: Cancer Biomarkers Testing Solutions Portfolio
Table 8.37 MedGenome: Company Overview
Table 8.38 MedGenome: Cancer Biomarkers Testing Solutions Portfolio
Table 8.39 NeoGenomics Laboratories: Company Overview
Table 8.40 NeoGenomics Laboratories: Cancer Biomarkers Testing Solutions Portfolio
Table 8.41 Nonacus: Company Overview
Table 8.42 Nonacus: Cancer Biomarkers Testing Solutions Portfolio
Table 8.43 Oxford Gene Technology: Company Overview
Table 8.44 Oxford Gene Technology: Cancer Biomarkers Testing Solutions Portfolio
Table 8.45 Personal Genome Diagnostics: Company Overview
Table 8.46 Personal Genome Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
Table 8.47 PhenoPath: Company Overview
Table 8.48 PhenoPath: Cancer Biomarkers Testing Solutions Portfolio
Table 8.49 Positive Biosciences: Company Overview
Table 8.50 Positive Biosciences: Cancer Biomarkers Testing Solutions Portfolio
Table 8.51 Quest Diagnostics: Company Overview
Table 8.52 Quest Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
Table 8.53 Tempus: Company Overview
Table 8.54 Tempus: Cancer Biomarkers Testing Solutions Portfolio
Table 20.1 Cell IDx: Company Snapshot
Table 20.2 CeGat: Company Snapshot
Table 20.3 NeoGenomics Laboratories: Company Snapshot
Table 21.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
Table 21.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
Table 21.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Table 21.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Table 21.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
Table 21.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Table 21.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Table 21.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
Table 21.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Table 21.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Table 21.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Table 21.12 Agilent: Annual Revenues, FY 2019–FY 2023 (USD Million)
Table 21.13 Thermo Fisher Scientific: Annual Revenues, FY 2019–FY 2023 (USD Million)
Table 21.14 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Table 21.15 Clinical Trial Analysis: Distribution by Trial Status
Table 21.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
Table 21.17 Clinical Trial Analysis: Distribution by Trial Phase
Table 21.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
Table 21.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
Table 21.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 21.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 21.22 Clinical Trial Analysis: Distribution by Study Design
Table 21.23 Clinical Trial Analysis: Distribution by Type of Cancer
Table 21.24 Most Active Players: Distribution by Number of Registered Trials
Table 21.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 21.26 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 21.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 21.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 21.29 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Table 21.30 Publication Analysis: Distribution by Type of Publication
Table 21.31 Publication Analysis: Distribution by Type of Cancer
Table 21.32 Most Popular Copyright Holders: Distribution by Number of Publications
Table 21.33 Most Active Publishers: Distribution by Number of Publications
Table 21.34 Key Journals: Distribution by Number of Publications
Table 21.35 Key Journals: Distribution by Impact Factor
Table 21.36 Benchmarking Analysis: Big Pharma players
Table 21.37 Global Cancer Biomarkers Market, Historical Trends (2018-2023) (USD Billion)
Table 21.38 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.39 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035 (USD Billion)
Table 21.40 Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.41 Cancer Biomarkers Market for HER2 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.42 Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.43 Cancer Biomarkers Market for MET Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.44 Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.45 Cancer Biomarkers Market for EGFR Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.46 Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.47 Cancer Biomarkers Market for PD-L1 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.48 Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.49 Cancer Biomarkers Market for NTRK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.50 Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.51 Cancer Biomarkers Market for ALK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.52 Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.53 Cancer Biomarkers Market for Other Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.54 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035 (USD Billion)
Table 21.55 Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.56 Cancer Biomarkers Market for SNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.57 Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.58 Cancer Biomarkers Market for MSI Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.59 Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.60 Cancer Biomarkers Market for CNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.61 Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.62 Cancer Biomarkers Market for TMB Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.63 Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.64 Cancer Biomarkers Market for TIL Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.65 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035 (USD Billion)
Table 21.66 Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.67 Cancer Biomarkers Market for Breast Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.68 Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.69 Cancer Biomarkers Market for Prostate Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.70 Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.71 Cancer Biomarkers Market for Colorectum Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.72 Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.73 Cancer Biomarkers Market for Lung Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.74 Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.75 Cancer Biomarkers Market for Thyroid Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.76 Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.77 Cancer Biomarkers Market for Bladder Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.78 Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) (USD Billion)
Table 21.79 Cancer Biomarkers Market for Melanoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.80 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) (USD Billion)
Table 21.81 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.82 Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.83 Cancer Biomarkers Market for Endometrial Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.84 Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.85 Cancer Biomarkers Market for Kidney Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.86 Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) (USD Billion)
Table 21.87 Cancer Biomarkers Market for Leukemia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.88 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
Table 21.89 Cancer Biomarkers Market in North America: Historical Trends (2018-2023) (USD Billion)
Table 21.90 Cancer Biomarkers Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.91 Cancer Biomarkers Market in the US: Historical Trends (2018-2023) (USD Billion)
Table 21.92 Cancer Biomarkers Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.93 Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) (USD Billion)
Table 21.94 Cancer Biomarkers Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.95 Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) (USD Billion)
Table 21.96 Cancer Biomarkers Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.97 Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) (USD Billion)
Table 21.98 Cancer Biomarkers Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.99 Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) (USD Billion)
Table 21.100 Cancer Biomarkers Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.101 Cancer Biomarkers Market in France: Historical Trends (2018-2023) (USD Billion)
Table 21.102 Cancer Biomarkers Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.103 Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) (USD Billion)
Table 21.104 Cancer Biomarkers Market in Spain: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.105 Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) (USD Billion)
Table 21.106 Cancer Biomarkers Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.107 Cancer Biomarkers Market in Asia-Pacific: Historical Trends (2018-2023) (USD Billion)
Table 21.108 Cancer Biomarkers Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.109 Cancer Biomarkers Market in China: Historical Trends (2018-2023) (USD Billion)
Table 21.110 Cancer Biomarkers Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.111 Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) (USD Billion)
Table 21.112 Cancer Biomarkers Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.113 Cancer Biomarkers Market in India: Historical Trends (2018-2023) (USD Billion)
Table 21.114 Cancer Biomarkers Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.115 Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) (USD Billion)
Table 21.116 Cancer Biomarkers Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.117 Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) (USD Billion)
Table 21.118 Cancer Biomarkers Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.119 Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) (USD Billion)
Table 21.120 Cancer Biomarkers Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.121 Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) (USD Billion)
Table 21.122 Cancer Biomarkers Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.123 Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) (USD Billion)
Table 21.124 Cancer Biomarkers Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.125 Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) (USD Billion)
Table 21.126 Cancer Biomarkers Market in Argentina: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.127 Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) (USD Billion)
Table 21.128 Cancer Biomarkers Market in Chile: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.129 Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) (USD Billion)
Table 21.130 Cancer Biomarkers Market in Egypt: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)

List Of Companies And Organizations

The following companies and organizations have been mentioned in the report.

  1. Aalborg University
  2. Abbott
  3. AbbVie
  4. Agilent
  5. Ambry Genetics
  6. American Association for Cancer Research (AACR)
  7. American Society of Clinical Oncology
  8. Amgen
  9. ARUP Laboratories
  10. Asper Biogene
  11. AstraZeneca
  12. Bayer
  13. Baylor Genetics
  14. Biocartis
  15. Bio-Rad
  16. BioReference
  17. Boehringer Ingelheim
  18. Bristol Myers Squibb
  19. Caris Life Sciences
  20. CBLPath
  21. CeGaT
  22. Cancer Treatment Options and Management (CTOAM)
  23. Eli Lilly
  24. Epic Sciences
  25. Exact Sciences
  26. Foundation Medicine
  27. Genekor Medical
  28. Genentech
  29. Genomics For Life
  30. GenPath Oncology
  31. Gilead
  32. GlaxoSmithKline
  33. Guardant Health
  34. Impact Genetics
  35. Invitae
  36. Iovance Biotherapeutics
  37. Jiangsu Hengrui Pharmaceuticals
  38. John Wiley & Sons
  39. Junshi Biosciences
  40. KEW
  41. Labcorp
  42. MedGenome
  43. Merck
  44. Metropolis Healthcare
  45. Myriad Genetics
  46. NantHealth
  47. Natera
  48. National Cancer Institute (NCI)
  49. NeoGenomics Laboratories
  50. Nonacus
  51. Novartis
  52. Novogene
  53. Odense University Hospital (OUH)
  54. OncoDNA
  55. Oncophenomics
  56. Onkogenetiks
  57. Oxford Gene Technology
  58. Paragon Genomics
  59. Personal Genome Diagnostics
  60. Personalis
  61. Pfizer
  62. PhenoPath
  63. Positive Biosciences
  64. Predicine
  65. Promega
  66. Q² Solutions
  67. Quest Diagnostics
  68. Roche
  69. SAGE Publications
  70. Sanofi
  71. Shanghai Tenth People's Hospital
  72. SOPHiA GENETICS
  73. Sun Yat-sen University
  74. Synnovis
  75. Tempus
  76. Thermo Fisher Scientific
  77. Tongji Hospital
  78. Translational Cancer Research
  79. United States Department of Defense
  80. YuceBio

 

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com